Friday, June 30, 2017 10:02:06 AM
I do believe it is "directionally" correct, in the sense that the actipatch likely provides an net cost reduction for patients. To claim a 41% cost reduction based on only 30 subjects, to me, is kind of like a head scratcher... Why in the world would you only study 30 subjects? Another half ass test by BIEL. if they are going to do this economic test, make it more credible with a larger sample set. Minimum 100 people from each age brackets, and with varying types of healthcare coverage / prescription coverage.
This test, as a 30 subject test, just based on UK subjects, is a flat out garbage job buy BIEL, and another fluff PR to any one with common sense.
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM